Trending Technology | Novel Networks & Finance | Produce & Use
LIVE ONLINE 7 October 2021
Advanced Therapies Integrates 2021 Agenda
7th OCTOBER 2021
ALL SESSIONS WILL BE PRESENTED AS PANEL DISCUSSIONS
PLEASE NOTE: Timings may be subject to change.
SESSIONS ARE DIVIDED INTO 3 TRACKS.
DELEGATES WILL BE FREE TO CHOOSE FROM TRACK 1, 2 or 3 AT ANY TIME.
Opening
09:15-09:30
Welcome and Opening Remarks
SHARON BROWNLOW | Chief Business Officer | Cell & Gene Therapy Catapult
TRENDING TECHNOLOGY
NOVEL NETWORKS & FINANCE
PRODUCE AND USE
Session 1
09:35- 10:25
Navigating the regulatory maze
Cell and gene therapies raise specific challenges to securing regulatory approvals. This session will look in detail at those challenges and provide insight into effective regulatory strategies.
Finding the Funds
Are the existing approaches to financing ATMP developers fit for purpose; what should analysts really be looking for in an Advanced Therapy?
Making Waves: Technologies and development improvements
How good are we at making Advanced Therapies today, what should the future look like?
Session 2
10:35-11:25
Britain’s talent for technology
Does the UK have the right skills and capabilities in place to identify and develop the next generation of ATMPs?
Advanced Relays
Evolving the relationship between developers, regulators, payers, providers and patients to speed ATMP development through to adoption.
Supply Pain
As more ATMPs progress towards the market, there are significant emergent challenges to the supply chain.
Break
11:30 – 11:50
NETWORKING
Session 3
11:55-12:45
Getting to Market
A Discussion on Challenges, Opportunities and Market Access within Advanced Therapies; how do we create a robust market economy for Advanced therapies, taking into account costs of goods, manufacture and procurement. Do we need a new business model?
Market forces or forcing the market
What are the current challenges and future opportunities for opening up the ATMP markets?
Productive People
As manufacturing technologies continues to emerge, we must have the skills to deliver the science at scale. How can we ensure that talent tracks with emergent manufacturing trends?
Session 4
12:55-13:45
Go with the (cash) flow
Investments and infrastructure have been put in place to rapidly translate ATMPs from concept to clinic. But are we doing enough?
Due process: GMP translation and manufacture
Shortening upstream and downstream process is key to cost and natural resource savings and efficiencies for ATMPs.
Break
13:50-14:20
NETWORKING
Session 5
14:25-15:15
Fast Forward
What are the emerging therapeutic technologies and what will the next generation of ATMPs look like? Do we have the right capabilities and assets to manufacture them?
Skills: the global gold rush
How can stakeholders come together to address cell and gene therapy’s global talent gap?
Negotiate or collaborate?
In an ever-changing pharmaceutical landscape, successfully bringing a concept to market — and to patients — involves many different stakeholders. How do industry leaders navigate this journey most effectively?
Closing
15:20-15:30
Closing remarks
SHARON BROWNLOW | Chief Business Officer | Cell & Gene Therapy Catapult
Welcome and Opening Remarks
09:15-09:30
SHARON BROWNLOW | Chief Business Officer | Cell & Gene Therapy Catapult
TRENDING TECHNOLOGY
Session 1:
09:35- 10:25
Let’s get clinical
- Evaluation and Development for ATMPs is different from the ‘norm’; do we need to rethinking the design of clinical trials for a clear path to commercialisation.
- Taking learnings from Covid-19 (vaccines), i.e., efficiency in a crisis – what can we learn?
Session 2:
10:35-11:25
Britain’s talent for technology
Does the UK have the right skills and capabilities in place to identify and develop the next generation of ATMPs?
NETWORKING
11:30-11:50
Session 3:
11:55-12:45
Precision Thinking
How to expand the development and use of Autologus ATMPs.
NETWORKING
13:50-14:20
Session 5:
14:25-15:15
Fast Forward
What are the emerging therapeutic technologies and what will the next generation of ATMPs look like?
Do we have the right capabilities and assets to manufacture them?
Welcome and Opening Remarks
09:15-09:30
SHARON BROWNLOW | Chief Business Officer | Cell & Gene Therapy Catapult
NOVEL NETWORKS & FINANCE
Session 1:
09:35- 10:25
Finding the Funds
Are the existing approaches to financing ATMP developers fit for purpose; what should analysts really be looking for in an Advanced Therapy?
Session 2:
10:35-11:25
Advanced Relays
Evolving the relationship between developers, regulators, payers, providers and patients to speed ATMP development through to adoption. How healthy are the Technology Assessments for ATMPs, are they revealing the full value?
NETWORKING
11:30-11:50
Session 3:
11:55-12:45
Export Strength
What are the current challenges and future opportunities for opening up the ATMP markets?
MHRA, NICE and NHS England are working together can make the UK attractive, but there are lower number of patients in UK as opposed to Europe. So how attractive is the UK for investment? How can investors get quicker and better returns?
Divergence from MHRA and EMA
Session 4:
12:55-13:45
Go with the (cash) flow
Investments and infrastructure have been put in place to rapidly translate ATMPs from concept to clinic. But are we doing enough?
NETWORKING
13:50-14:20
Session 5:
14:25-15:15
Skills: the global gold rush
How can stakeholders come together to address cell and gene therapy’s global talent gap?
Welcome and Opening Remarks
09:15-09:30
SHARON BROWNLOW | Chief Business Officer | Cell & Gene Therapy Catapult
PRODUCE AND USE
Session 1:
09:35- 10:25
Making Waves: Technologies and development improvements
How good are we at making Advanced Therapies today, what should the future look like?
Focusing on manufacturing technologies and analytical methods and the role of High throughput and automation.
Session 2:
10:35-11:25
Supply Pain
As more ATMPs progress towards the market, there are significant emergent challenges to the supply chain.
What needs to happen to ensure therapies are effectively and efficiently produced?
NETWORKING
11:30-11:50
Session 3:
11:55-12:45
Productive People
As manufacturing technologies continues to emerge, we must have the skills to deliver the science at scale. How can we ensure that talent tracks with emergent manufacturing trends?
Session 4:
12:55-13:45
Due process: GMP translation and manufacture
Shortening upstream and downstream process is key to cost and natural resource savings and efficiencies for ATMPs. Can we share knowledge for the greater good of patients and the planet?
NETWORKING
13:50-14:20
Session 5:
14:25-15:15
Negotiate or collaborate?
In an ever-changing pharmaceutical landscape, successfully bringing a concept to market — and to patients — involves many different stakeholders. How do industry leaders navigate this journey most effectively?
Sign up for life science integrates news
Get the latest news and updates by signing up today.
By signing up to the life science integrates newsletter, you have read and agree to our Privacy Policy, including our Cookie use.
Trending Technology | Novel Networks & Finance | Produce & Use